Studying endometrial cancer samples to predict response to PARP inhibitors
Collects tumour and blood samples from adults with endometrial cancer to model treatment response.
Key facts
- Who runs it
- Centre Francois Baclesse
- Where
- Caen, FranceSee the site
- Trial code
- Registry title
- Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
- Status
- Recruiting
- People taking part
- 16 people, planned
- Started
- 21 Nov 2024
- Expected to end
- 15 Oct 2027
- Type of study
- Observational
- Treatments tested
- tumour and blood samples
- Record updated
- 26 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with localized endometrial cancer who are planned for surgery and have a higher-risk tumor type. Their tumor and blood samples are collected.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Localized endometrial cancer, confirmed by tissue examination, with surgery planned. It must be a high-grade endometrioid type, and/or have a P53 mutation, and/or be a non-endometrioid type whatever the P53 status.
- Biomarker or test result
- P53 mutation, unless the tumor is a non-endometrioid type, where P53 status does not matter.
Main reasons for not taking part
- Another active cancer diagnosed less than 6 months ago (treated basal cell skin cancer is allowed)
- Deprived of liberty, under guardianship or legal protection, or unable to give consent
The registry criteria, word for word
Show all 7 criteriaShow less
Who can take part
- Patient aged 18 years or more
- Patient with histologically confirmed, localized endometrial cancer, candidate for surgical treatment
- Patient with localized endometrial cancer, presenting:; A high-grade endometrioid histological type and/or; P53 mutation and/or; a non-endometrioid histological type regardless of P53 status
- Patient affiliated to a social security scheme
- Information and signature of informed consent prior to any specific study procedure
Who cannot take part
- Other active cancer less than 6 months old (with the exception of treated basal cell carcinoma of the skin)
- Patient deprived of liberty, under guardianship, or subject to a legal protection measure, or unable to express consent
Where in France
- Centre François BaclesseCaen, FranceContact: Gwenn LE GALL, Medical DoctorTaking people
About the trial
What the trial wants to find out
This study comprises 3 stages:
Read full original descriptionShow less
1. Collection of tumor and blood samples. 2. Creation of organoid models based on tumor samples. 3. Development of functional tests to predict clinical response to treatment.
The group in the trial
- tumour and blood collection
tumour and blood collection for realization ex vivo organoid models
Treatment: tumour and blood samples
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
- Plain-language title
- Studying endometrial cancer samples to predict response to PARP inhibitorsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 November 2024